Chardan Capital Markets initiates coverage on Dicerna Pharmaceuticals (NASDAQ: DRNA) with a Neutral rating saying new investors should wait for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE